T Lymphocyte Dynamics in Early Alzheimer's Disease Pathology
Overview
This commentary highlights altered T cell immunity in early Alzheimer's disease (AD), focusing on increased CD8+ TEMRA cells and changes in CD4+ T cell subsets in amyloid-positive individuals. These immune alterations correlate with disease stage and cognitive impairment, suggesting a complex role of adaptive immunity in AD progression.
Background
Alzheimer’s disease is characterized by progressive neurodegeneration and amyloid pathology, with growing evidence implicating immune system involvement. While microglia have been extensively studied, adaptive immune cells such as T lymphocytes are gaining attention for their potential role in disease progression. Recent genetic studies have identified immune-related risk factors, and emerging data suggest that T cell phenotypes and functions change in early AD stages. Understanding these changes may reveal novel therapeutic targets.
CD8+ TEMRA cells are significantly increased in blood and CSF of amyloid-positive individuals, with highest levels in MCI+ participants.
CD8+ TEMRA cells from MCI+ individuals exhibit a pro-inflammatory gene profile compared to HCS+.
CD4+ T cell subsets, including central memory, effector memory, and regulatory T cells, show reduced pro-inflammatory and anti-inflammatory gene expression in amyloid-positive groups.
There is an inverse relationship between CD8+ TEMRA expansion and CD4+ regulatory T cell decline in early AD stages.
Autoreactive CD4+ memory T cell responses to amyloid-beta peptides are present in both amyloid-positive and negative cognitively unimpaired individuals but are diminished in MCI+ participants.
CMV seropositivity correlates with higher CD8+ TEMRA levels but does not fully explain differences between clinical groups.
Clinical Implications
These findings suggest that monitoring T cell subsets, particularly CD8+ TEMRA and CD4+ regulatory T cells, may provide biomarkers for early AD pathology and progression. Therapeutic strategies aimed at modulating T cell responses could potentially alter disease trajectory. Understanding the antigenic targets and functional roles of these T cells is critical for developing immune-based interventions.
Conclusion
Altered T lymphocyte dynamics, including expansion of cytotoxic CD8+ TEMRA cells and changes in CD4+ T cell populations, characterize early stages of Alzheimer’s disease and may influence disease progression. These immune alterations offer promising avenues for biomarker development and immunomodulatory therapies.
